Peter Langford began work at DAVA in 2015, during which time, he has filled many roles for the company. He has managed the ONE Medical Writing Team since February 2017. Prior to joining DAVA, Dr. Langford worked at DAVA’s sister company, AROG, performing pharmacokinetic analyses for AROG’s trials in AML.
Dr. Langford received his B.S. and his Ph.D., both in Physiology and Developmental Biology from Brigham Young University, Provo in 2011, where he combined pharmacology, electrophysiology, and cancer cell biology to identify and inhibit previously unidentified components of the c-Met signaling pathway.
After graduation, Dr. Langford worked as a postdoctoral fellow in two cancer cell laboratories at Johns Hopkins Medical School, where he investigated signaling pathways in pancreatic cancer and novel treatment strategies in breast cancer.
January 15, 2019